The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival
Open accessAbstract
Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells are found closely associated with bone, and targeting this environment may therefore affect both the bone disease and the growth of myeloma cells. We have investigated the effect of the potent bisphosphonate, zoledronic acid, on the development of bone disease, tumor burden, and disease-free survival in the 5T2MM model of myeloma. 5T2MM murine myeloma cells were injected intravenously into C57BL/KaLwRij mice. After 8 weeks, all animals had a paraprotein. Animals were treated with zoledronic acid (120 μg/kg, subcutaneously, twice weekly) or vehicle, from the time of tumor cell injection or from paraprotein detection for 12 or 4 weeks, respectively. All animals injected with tumor cells developed osteolytic lesions, a decrease in cancellous bone volume, an increase in osteoclast perimeter, and a decrease in bone mineral density. Zoledronic acid prevented the formation of lesions, prevented cancellous bone loss and loss of bone mineral density, and reduced osteoclast perimeter. Zoledronic acid also decreased paraprotein concentration, decreased tumor burden, and reduced angiogenesis. In separate experiments, Kaplan-Meier analysis demonstrated a significant increase in survival after treatment with zoledronic acid when compared with control (47 vs. 35 days). A single dose of zoledronic acid was also shown to be effective in preventing the development of osteolytic bone disease. These data show that zoledronic acid is able to prevent the development of osteolytic bone disease, decrease tumor burden in bone, and increase survival in a model of established myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Self-citationFisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Kunzmann, V., Bauer, E., Feurle, J., Tony, F. W., & Wilhelm, M. (2000) · Blood · doi:10.1182/blood.v96.2.384 · Cited by 669
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Self-citationChoi, S. J., Cruz, J. C., Craig, F., Chung, H., Devlin, R. D., Roodman, G. D., & Alsina, M. (2000) · Blood · doi:10.1182/blood.v96.2.671 · Cited by 408
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2713086.x · Cited by 398
Self-citationγ/δ T-Cell Stimulation by Pamidronate
Kunzmann, V., Bauer, E., & Wilhelm, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400914 · Cited by 395
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Self-citationProduction of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma Cells
Garrett, I. R., Durie, B. G. M., Nedwin, G. E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D. R., & Mundy, G. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708273170902 · Cited by 373
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., & Lichtenstein, A. (1998) · Leukemia · doi:10.1038/sj.leu.2400892 · Cited by 259
Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J., & Alexandre, C. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115305 · Cited by 253
Shipman, C. M., Croucher, P. I., Russell, R. G. G., Helfrich, M. H., & Rogers, M. J. (1998) · PubMed · Cited by 216
Self-citationHepatocyte growth factor and its receptor c-met in multiple myeloma
Borset, M., Hjorth-Hansen, H., Seidel, C., Sundan, A., & Waage, A. (1996) · Blood · doi:10.1182/blood.v88.10.3998.bloodjournal88103998 · Cited by 209
Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.-L., & Bataille, R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2048 · Cited by 195
Taube, T., Beneton, M. N. C., McCloskey, E. V., Rogers, S., Greaves, M., & Kanis, J. A. (1992) · European Journal of Haematology · doi:10.1111/j.1600-0609.1992.tb00046.x · Cited by 194
Production of interleukin-1 by bone marrow myeloma cells
Cozzolino, F., Torcia, M., Aldinucci, D., Rubartelli, A., Miliani, A., Shaw, A., Lansdorp, P., & Di Guglielmo, R. (1989) · Blood · doi:10.1182/blood.v74.1.380.380 · Cited by 185
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02851.x · Cited by 181
Vγ2Vδ2 T-cell receptor–mediated recognition of aminobisphosphonates
Das, H., Wang, L., Kamath, A., & Bukowski, J. F. (2001) · Blood · doi:10.1182/blood.v98.5.1616 · Cited by 178
Quantitative histology of myeloma‐induced bone changes
Valentin‐Opran, A., Charhon, S. A., Meunier, P. J., Edouard, C. M., & Arlot, M. E. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb03936.x · Cited by 178
Animal model of human disease. Multiple myeloma.
Radl, J., Croese, J. W., ZURCHER, C., van den Enden-Vieveen, M. H. M., & Leeuw, A. M. D. (1988) · PubMed Central · Cited by 174
Radl, J., de Glopper, E., Schuit, H. R. E., & ZURCHER, C. (1979) · PubMed · Cited by 161
Vanderkerken, K., Raeve, H. D., Goes, E., Meirvenne, S. V., Radl, J., Riet, I. V., Thielemans, K., & Camp, B. V. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.409 · Cited by 153
Self-citationThe 5TMM series: a useful in vivo mouse model of human multiple myeloma
Asosingh, K., Radl, J., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200052 · Cited by 143
Self-citationDallas, S. L., Garrett, I. R., Oyajobi, B. O., Dallas, M. R., Boyce, B. F., Bauss, F., Radl, J., & Mundy, G. R. (1999) · Blood · doi:10.1182/blood.v93.5.1697 · Cited by 137
Tassone, P., Forciniti, S., Galea, E., Morrone, G., Turco, M. C., Martinelli, V., Tagliaferri, P., & Venuta, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401770 · Cited by 136
Børset, M., Lien, E., Espevik, T., Helseth, E., Waage, A., & Sundan, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24655 · Cited by 131
Kawano, M., Yamamoto, I., Iwato, K., Tanaka, H., Asaoku, H., Tanabe, O., Ishikawa, H., Nobuyoshi, M., Ohmoto, Y., & Hirai, Y. (1989) · Blood · doi:10.1182/blood.v73.6.1646.1646 · Cited by 122
Brincker, H., Westin, J., Abildgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J., & Kandra, A. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00695.x · Cited by 114
Radl, J., de Glopper, E., Schuit, H. R. E., & ZURCHER, C. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.122.2.609 · Cited by 100
Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells
Vanderkerken, K., Asosingh, K., Braet, F., Riet, I. V., & Camp, B. V. (1999) · Blood · doi:10.1182/blood.v93.1.235 · Cited by 92
Self-citationRoux, C., Ravaud, P., Cohen-Solal, M. E., de Vernejoul, M. C., Guillemant, S., Cherruau, B., Delmas, P. D., Dougados, M., & Amor, B. (1994) · Bone · doi:10.1016/8756-3282(94)90890-7 · Cited by 81
Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo
Valckenborgh, E. V., Raeve, H. D., Devy, L., Blacher, S., Munaut, C., Noël, A., Marck, E. V., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600137 · Cited by 52
Self-citationCruz, J. C., Alsina, M., Craig, F. E., Yoneda, T., Anderson, J. L., Dallas, M., & Roodman, G. D. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00618-x · Cited by 37
Shipman, C. M., Holen, I., Lippitt, J. M., Vandenberghe, E., & Croucher, P. I. (2000) · Blood · Cited by 17
Self-citation
Cited by
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S. E., Szubert, A. J., Navarro-Coy, N., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Bone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Self-citationYaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-09-047712 · Cited by 433
Metadata
- Authors
- Croucher, P. I., De Raeve, H., Perry, M. J., Hijzen, A., Shipman, C. M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B., & Vanderkerken, K.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03-01
- Volume
- 18
- Issue
- 3
- Pages
- 482-492
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2031650256
- Cited by
- 266
- References
- 48
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.